

# Nick Holford Mbchb, Fracp

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4325857/nick-holford-mbchb-fracp-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162  
papers

10,846  
citations

57  
h-index

102  
g-index

171  
ext. papers

11,896  
ext. citations

4.1  
avg, IF

6.51  
L-index

#	Paper	IF	Citations
162	Disease progress models <b>2022</b> , 389-403		
161	Time course of drug response <b>2022</b> , 377-387		
160	Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2021</b> , 1	2.7	2
159	TDM is dead. Long live TCI!. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> ,	3.8	14
158	The Effect of Size, Maturation, Global Asphyxia, Cerebral Ischemia, and Therapeutic Hypothermia on the Pharmacokinetics of High-Dose Recombinant Erythropoietin in Fetal Sheep. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
157	Pharmacometrics in Australasia-Twenty Years of Population Approach Group of Australia and New Zealand. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2019</b> , 8, 701-704	4.5	1
156	Treatment response and disease progression. <i>Translational and Clinical Pharmacology</i> , <b>2019</b> , 27, 123-126		1
155	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. <i>Transplantation</i> , <b>2019</b> , 103, 2012-2030	1.8	19
154	Pharmacodynamic principles and target concentration intervention. <i>Translational and Clinical Pharmacology</i> , <b>2018</b> , 26, 150-154	2	11
153	Pharmacodynamic principles and the time course of delayed and cumulative drug effects. <i>Translational and Clinical Pharmacology</i> , <b>2018</b> , 26, 56-59	2	6
152	Negligible impact of birth on renal function and drug metabolism. <i>Paediatric Anaesthesia</i> , <b>2018</b> , 28, 1015-1021	1.8	12
151	Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1758-1772	3.8	42
150	Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 823-835	3.8	23
149	Allometric size: The scientific theory and extension to normal fat mass. <i>European Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 109S, S59-S64	5.1	69
148	What is the best size predictor for dose in the obese child?. <i>Paediatric Anaesthesia</i> , <b>2017</b> , 27, 1176-1184	1.8	36
147	Pharmacodynamic principles and the time course of immediate drug effects. <i>Translational and Clinical Pharmacology</i> , <b>2017</b> , 25, 157-161	2	16
146	Response to R-warfarin anticoagulant effect. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 2305-2306	5.8	2

145	Pharmacokinetic variability due to environmental differences. <i>Translational and Clinical Pharmacology</i> , <b>2017</b> , 25, 59-62	2	3
144	Volume of Distribution. <i>Translational and Clinical Pharmacology</i> , <b>2016</b> , 24, 74	2	9
143	Absorption and Half-Life. <i>Translational and Clinical Pharmacology</i> , <b>2016</b> , 24, 157	2	2
142	Quantitative model for the blood pressure-lowering interaction of valsartan and amlodipine. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1557-1567	3.8	5
141	Dexmedetomidine pharmacokinetics in the obese. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1501-8	2.8	40
140	Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 1287-8	6.2	9
139	Clinical pharmacology = disease progression + drug action. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 18-27	3.8	24
138	Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 1475-6	3.8	2
137	A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children. <i>Frontiers in Pharmacology</i> , <b>2015</b> , 6, 151	5.6	6
136	Clearance. <i>Translational and Clinical Pharmacology</i> , <b>2015</b> , 23, 42	2	8
135	Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 167-78	6.2	35
134	Postoperative analgesia using diclofenac and acetaminophen in children. <i>Paediatric Anaesthesia</i> , <b>2014</b> , 24, 953-61	1.8	27
133	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 509-23	3.8	58
132	Population Pharmacokinetic and Pharmacodynamic Methods <b>2014</b> , 551-569		
131	Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 754-63	12.9	94
130	Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2014</b> , 41, 15-33	2.7	34
129	Importance of hematocrit for a tacrolimus target concentration strategy. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 65-77	2.8	72
128	The International Society of Pharmacometrics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2013</b> , 40, 3-4	2.7	2

127	The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1411-21	2.8	24
126	Disease progression and neuroscience. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2013</b> , 40, 369-76	2.7	7
125	A pharmacokinetic standard for babies and adults. <i>Journal of Pharmaceutical Sciences</i> , <b>2013</b> , 102, 2941-53.	3.9	216
124	A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models. <i>Pharmaceutical Statistics</i> , <b>2013</b> , 12, 129-40	1	52
123	Understanding dosing: children are small adults, neonates are immature children. <i>Archives of Disease in Childhood</i> , <b>2013</b> , 98, 737-44	2.2	118
122	External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 1068-80	3.8	76
121	Authors' response to Marras and Oakes, 'Piecing together the puzzle of progression and mortality in Parkinson's disease'. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 1370-1	3.8	1
120	A time to event tutorial for pharmacometricians. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2013</b> , 2, e43	4.5	57
119	Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models". <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 873-4	3.2	
118	Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2013</b> , 2, e69	4.5	13
117	Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 267-83	3.8	102
116	Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 284-95	3.8	38
115	Disease Progress Models <b>2012</b> , 369-379		1
114	Time Course of Drug Response <b>2012</b> , 357-367		
113	Prediction of morphine dose in humans. <i>Paediatric Anaesthesia</i> , <b>2012</b> , 22, 209-22	1.8	55
112	Modeling helps in understanding antidepressants. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 1556-61	4.1	3
111	The ghosts of departed quantities: approaches to dealing with observations below the limit of quantitation. <i>Statistics in Medicine</i> , <b>2012</b> , 31, 4280-95	2.3	21
110	The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 689-95	2.8	42

109	Safe and effective variability-a criterion for dose individualization. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 565-8	3.2	61
108	Predicting weight using postmenstrual age--neonates to adults. <i>Paediatric Anaesthesia</i> , <b>2011</b> , 21, 309-15	1.8	31
107	Tips and traps analyzing pediatric PK data. <i>Paediatric Anaesthesia</i> , <b>2011</b> , 21, 222-37	1.8	116
106	Evaluation of a morphine maturation model for the prediction of morphine clearance in children. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 72, 518-20; author reply 521-3	3.8	3
105	Response to Validation and Assessment of Predictive Performance in Simulation Models of Clinical Trials <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 488-488	6.1	1
104	Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models", <i>Clin Pharmacokin</i> 6:429-453 (1981)-The Backstory. <i>AAPS Journal</i> , <b>2011</b> , 13, 662-4	3.7	16
103	A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 1145-55	3.5	23
102	The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4122-7	5.9	101
101	Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 70, 682-93	3.8	24
100	Dosing in children. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 87, 367-70	6.1	55
99	Clinical trial simulation: a review. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 88, 166-82	6.1	124
98	Leaving no stone unturned, or extracting blood from stone?. <i>Paediatric Anaesthesia</i> , <b>2010</b> , 20, 1-6	1.8	9
97	Dexmedetomidine hemodynamics in children after cardiac surgery. <i>Paediatric Anaesthesia</i> , <b>2010</b> , 20, 425-33	1.8	58
96	Review: efficient rehabilitation trial designs using disease progress modeling: a pediatric traumatic brain injury example. <i>Neurorehabilitation and Neural Repair</i> , <b>2010</b> , 24, 225-34	4.7	8
95	Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. <i>British Journal of Anaesthesia</i> , <b>2010</b> , 105, 448-56	5.4	127
94	Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. <i>Neurology</i> , <b>2010</b> , 74, 1191-7	6.5	40
93	Mechanistic basis of using body size and maturation to predict clearance in humans. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2009</b> , 24, 25-36	2.2	344
92	Human renal function maturation: a quantitative description using weight and postmenstrual age. <i>Pediatric Nephrology</i> , <b>2009</b> , 24, 67-76	3.2	349

91	Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. <i>Pharmaceutical Statistics</i> , <b>2009</b> , 8, 225-38	1	39
90	Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 66, 352-65	3.8	14
89	Mechanism-based concepts of size and maturity in pharmacokinetics. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2008</b> , 48, 303-32	17.9	774
88	A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4213-8	12.9	63
87	Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. <i>British Journal of Anaesthesia</i> , <b>2008</b> , 101, 680-9	5.4	135
86	Investigating the pharmacodynamics of ketamine in children. <i>Paediatric Anaesthesia</i> , <b>2008</b> , 18, 36-42	1.8	48
85	Disease progression, drug action and Parkinson's disease: why time cannot be ignored. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 207-16	2.8	25
84	Does saturable formation of gemcitabine triphosphate occur in patients?. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 63, 55-64	3.5	18
83	Pharmacometrics: The Science of Quantitative Pharmacology by E. I. Ette and P. J. Williams. <i>Biometrics</i> , <b>2008</b> , 64, 313-313	1.8	
82	Time Course of Drug Response <b>2007</b> , 301-311		0
81	Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 82, 103-5	6.1	13
80	Modeling the norketamine metabolite in children and the implications for analgesia. <i>Paediatric Anaesthesia</i> , <b>2007</b> , 17, 831-40	1.8	45
79	Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 75-84	3.8	123
78	PKPD model of interleukin-21 effects on thermoregulation in monkeys--application and evaluation of stochastic differential equations. <i>Pharmaceutical Research</i> , <b>2007</b> , 24, 298-309	4.5	13
77	Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. <i>Pharmaceutical Research</i> , <b>2007</b> , 24, 791-802	4.5	54
76	Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 7126-32	12.9	20
75	Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. <i>Journal of Clinical Pharmacology</i> , <b>2007</b> , 47, 227-37	2.9	24
74	Disease Progress Models <b>2007</b> , 313-321		4

73	Dose Response: Pharmacokinetic/Pharmacodynamic Approach <b>2006</b> , 73-88		4
72	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. <i>Blood</i> , <b>2006</b> , 108, 3674-81	2.2	224
71	Limited predictability of amikacin clearance in extreme premature neonates at birth. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 39-48	3.8	60
70	Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. <i>Pharmaceutical Research</i> , <b>2006</b> , 23, 2050-9	4.5	42
69	Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2006</b> , 33, 281-311	2.7	78
68	Simulation of correlated continuous and categorical variables using a single multivariate distribution. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2006</b> , 33, 773-94	2.7	22
67	Population clinical pharmacology of children: general principles. <i>European Journal of Pediatrics</i> , <b>2006</b> , 165, 741-6	4.1	76
66	Population clinical pharmacology of children: modelling covariate effects. <i>European Journal of Pediatrics</i> , <b>2006</b> , 165, 819-29	4.1	136
65	Analysis of population pharmacokinetic data using NONMEM and WinBUGS. <i>Journal of Biopharmaceutical Statistics</i> , <b>2005</b> , 15, 53-73	1.3	47
64	Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2005</b> , 32, 307-31	2.7	21
63	Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2005</b> , 32, 459-84	2.7	25
62	Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. <i>British Journal of Anaesthesia</i> , <b>2004</b> , 92, 208-17	5.4	232
61	Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 58, 8-19	3.8	82
60	Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2004</b> , 31, 243-68	2.7	23
59	Paracetamol and metabolite pharmacokinetics in infants. <i>European Journal of Clinical Pharmacology</i> , <b>2003</b> , 59, 243-51	2.8	66
58	Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 55, 147-57	3.8	46
57	Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , <b>2002</b> , 17, 961-8	7	59
56	Clinical pharmacology: principles and practice of drug therapy in medical education. <i>British Journal of Clinical Pharmacology</i> , <b>2002</b> , 54, 1-2	3.8	8

55	Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 334-48	6.1	68
54	Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. <i>Anesthesiology</i> , <b>2002</b> , 96, 1336-45	4.3	188
53	Determination of maximum effect. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 304; author reply 304-5	6.1	5
52	A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats. <i>Pharmaceutical Research</i> , <b>2001</b> , 18, 1174-84	4.5	13
51	Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. <i>European Journal of Clinical Pharmacology</i> , <b>2001</b> , 57, 559-69	2.8	108
50	Drug treatment effects on disease progression. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2001</b> , 41, 625-59	17.9	138
49	Concentration controlled therapy. <i>International Congress Series</i> , <b>2001</b> , 1220, 135-144		2
48	A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. <i>British Journal of Clinical Pharmacology</i> , <b>2000</b> , 50, 125-34	3.8	123
47	Investigations using logistic regression models on the effect of the LMA on morphine induced vomiting after tonsillectomy. <i>Paediatric Anaesthesia</i> , <b>2000</b> , 10, 633-8	1.8	16
46	Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 568-77	6.1	53
45	Simulation of clinical trials. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2000</b> , 40, 209-34	17.9	191
44	Caffeine overdose in a premature infant: clinical course and pharmacokinetics. <i>Anaesthesia and Intensive Care</i> , <b>1999</b> , 27, 307-11	1.1	35
43	Pharmacokinetics of paracetamol in adults after cardiac surgery. <i>Anaesthesia and Intensive Care</i> , <b>1999</b> , 27, 615-22	1.1	22
42	Target concentration intervention: beyond Y2K. <i>British Journal of Clinical Pharmacology</i> , <b>1999</b> , 48, 9-13	3.8	62
41	A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. <i>Computer Methods and Programs in Biomedicine</i> , <b>1999</b> , 59, 19-29	6.9	285
40	Predicting concentrations in children presenting with acetaminophen overdose. <i>Journal of Pediatrics</i> , <b>1999</b> , 135, 290-5	3.6	67
39	Perioperative pharmacodynamics of acetaminophen analgesia in children. <i>Anesthesiology</i> , <b>1999</b> , 90, 411-23	4.3	144
38	The pharmacokinetics of theophylline in premature neonates during the first few days after birth. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 598-603	3.2	15



37	Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. <i>British Journal of Clinical Pharmacology</i> , <b>1998</b> , 46, 237-43	3.8	68
36	Features and toxicokinetics of clozapine in overdose. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 92-7	3.2	31
35	Rectal acetaminophen pharmacokinetics. <i>Anesthesiology</i> , <b>1998</b> , 88, 1131-3	4.3	3
34	Non-stationary pharmacokinetics of bupivacaine during continuous interpleural infusion. <i>Acute Pain</i> , <b>1997</b> , 1, 15-20		2
33	Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. <i>Clinical Pharmacokinetics</i> , <b>1997</b> , 33, 313-27	6.2	157
32	Relationship of muscle strength to potassium concentration in a hypokalaemic infant. <i>Anaesthesia and Intensive Care</i> , <b>1997</b> , 25, 525-7	1.1	3
31	Aspects of theophylline clearance in children. <i>Anaesthesia and Intensive Care</i> , <b>1997</b> , 25, 497-501	1.1	14
30	Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1997</b> , 39, 541-6	3.5	77
29	Rectal paracetamol dosing regimens: determination by computer simulation. <i>Paediatric Anaesthesia</i> , <b>1997</b> , 7, 451-5	1.8	76
28	A size standard for pharmacokinetics. <i>Clinical Pharmacokinetics</i> , <b>1996</b> , 30, 329-32	6.2	389
27	The response to levodopa in Parkinson's disease: imposing pharmacological law and order. <i>Annals of Neurology</i> , <b>1996</b> , 39, 561-73	9.4	253
26	Pharmacokinetics of rectal paracetamol after major surgery in children. <i>Paediatric Anaesthesia</i> , <b>1995</b> , 5, 237-42	1.8	83
25	The target concentration approach to clinical drug development. <i>Clinical Pharmacokinetics</i> , <b>1995</b> , 29, 287-91	6.2	58
24	Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. <i>Journal of Clinical Psychopharmacology</i> , <b>1995</b> , 15, 84S-94S	1.7	18
23	Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 11471-5	11.5	80
22	Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 11466-70	11.5	79
21	Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>1992</b> , 20, 421-42		39
20	Clinical pharmacokinetics of ethanol. <i>Clinical Pharmacokinetics</i> , <b>1987</b> , 13, 273-92	6.2	174

19	Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. <i>Clinical Pharmacokinetics</i> , <b>1986</b> , 11, 483-504	6.2	193
18	Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1984</b> , 9, 315-24	2.7	6
17	Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>1984</b> , 12, 559-73		25
16	Pharmacokinetics of quinidine and three of its metabolites in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>1984</b> , 12, 1-21		25
15	Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. <i>Kidney International</i> , <b>1984</b> , 25, 119-23	9.9	21
14	The absence of effect of azathioprine on prednisolone pharmacokinetics following maintenance prednisone doses in kidney transplant patients. <i>American Journal of Kidney Diseases</i> , <b>1984</b> , 3, 425-9	7.4	5
13	Opiate receptor binding-effect relationship: sufentanil and etorphine produce analgesia at the mu-site with low fractional receptor occupancy. <i>Brain Research</i> , <b>1984</b> , 291, 317-24	3.7	37
12	Dose-dependent elimination of propranolol and its major metabolites in humans. <i>Journal of Pharmaceutical Sciences</i> , <b>1983</b> , 72, 725-32	3.9	36
11	Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. <i>Journal of Pharmaceutical Sciences</i> , <b>1983</b> , 72, 1442-6	3.9	82
10	Kinetics of pharmacologic response <b>1982</b> , 16, 143-66		363
9	Relative bioavailability of chlorthalidone in humans: adverse influence of polyethylene glycol. <i>Journal of Pharmaceutical Sciences</i> , <b>1982</b> , 71, 533-5	3.9	5
8	Stereoselective disposition and glucuronidation of propranolol in humans. <i>Journal of Pharmaceutical Sciences</i> , <b>1982</b> , 71, 699-704	3.9	104
7	Prednisone and prednisolone bioavailability in renal transplant patients. <i>Kidney International</i> , <b>1982</b> , 21, 621-6	9.9	33
6	Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. <i>Clinical Pharmacokinetics</i> , <b>1981</b> , 6, 429-53	6.2	837
5	Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients. <i>European Journal of Clinical Pharmacology</i> , <b>1981</b> , 21, 235-42	2.8	48
4	Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine. <i>Journal of Pharmaceutical Sciences</i> , <b>1980</b> , 69, 1254-7	3.9	102
3	Gastrointestinal absorption of quinidine from some solutions and commercial tablets. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>1980</b> , 8, 243-55		5
2	Quinidine decreases both renal and metabolic clearance of digoxin. <i>American Journal of Cardiology</i> , <b>1980</b> , 45, 453	3	12

- 1 Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. *Journal of Pharmacokinetics and Pharmacodynamics*, **1979**, 7, 315-30 57